Verastem Poised for Breakout with Imminent FDA Approval
AI Prediction of Verastem, Inc. (VSTM)
Verastem, a biopharmaceutical company, is on the cusp of potentially transformative growth with its focus on RAS/MAPK pathway-driven cancers. The upcoming catalysts, including the possible FDA approval of its leading drug candidates avutometinib and defactinib for low-grade serous ovarian cancer, could significantly impact its market valuation and operational dynamics. Considering the strategic alignment with industry requirements and the anticipation surrounding its clinical results, Verastem presents a compelling investment opportunity with considerable upside potential.
VSTM Report Information
Prediction Date2025-07-03
Close @ Prediction$4.80
Mkt Cap480m
IPO DateN/a
AI-derived Information
Recent News for VSTM
- Apr 23, 7:30 am — Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
- Apr 10, 7:00 am — Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire)
- Apr 2, 4:05 pm — Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Mar 17, 6:03 pm — Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
- Mar 17, 4:44 pm — Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
- Mar 5, 8:30 am — Verastem, Inc. Q4 2025 Earnings Call Summary (Moby)
- Mar 5, 12:03 am — Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
- Mar 4, 8:48 pm — Verastem Q4 Earnings Call Highlights (MarketBeat)
- Mar 4, 5:10 pm — Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
- Mar 4, 4:20 pm — Verastem: Q4 Earnings Snapshot (Associated Press Finance)
- Mar 4, 4:01 pm — Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
- Feb 18, 7:30 am — Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
NDAPR (News-Driven AI Prediction Revision) events for VSTM
-
Apr 27, 4:23 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: VS-7375 mid-2026 data catalyst still pendingRationale: Catalyst progress. Q1 earnings scheduling may support commercial traction, but the original VS-7375 catalyst has not occurred and the August window remains intact.
-
Apr 10, 7:06 amRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason: Continued clinical progressRationale: Catalyst progress with sustained clinical benefits and safety profile.
-
Mar 17, 4:52 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: Catalyst progress.
-
Mar 9, 12:56 pmRevision: NO_CHANGE | Price Dir: NONE | Thesis: ACTIVE | Reason:Rationale: No new catalysts or significant changes affecting the original prediction were identified.
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.